UCB Announces U.S. FDA Approval of RYSTIGGO[®] (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis
What you need to know:
- This is a new therapy that is designed as a monoclonal antibody that binds to the neonatal Fc receptor (FcRN).
- The delivery of this therapy is subcutaneous injection – so it’s quicker and more convenient than infusion therapies that take hours.
- Rystiggo is approved to treat the most common type of MG (AChR-antibody) and also approved to treat MuSK-antibody (muscle-specific kinase) myasthenia – which is typically more severe and hasn’t responded as well to treatment.
For more information, talk to your health care provider.
Read the full press release [here].
